| Identification | Back Directory | [Name]
Cyclopropanecarboxamide, N-[6-bromo-5-(2-pyrimidinyl)-2-pyridinyl]-2,2-dimethyl-3-(2-methyl-1-propen-1-yl)-, (1S,3S)- | [CAS]
2365504-95-4 | [Synonyms]
(1S,3S)-N-(6-bromo-5-(pyrimidin-2-yl)pyridin-2-yl)-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane-1-carboxamide
Cyclopropanecarboxamide, N-[6-bromo-5-(2-pyrimidinyl)-2-pyridinyl]-2,2-dimethyl-3-(2-methyl-1-propen-1-yl)-, (1S,3S)- | [Molecular Formula]
C19H21BrN4O | [MDL Number]
MFCD34567820 | [MOL File]
2365504-95-4.mol | [Molecular Weight]
401.3 |
| Chemical Properties | Back Directory | [Boiling point ]
491.3±45.0 °C(Predicted) | [density ]
1.415±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
12.48±0.60(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
BRD-8000.3, as a specific EfpA inhibitor, is a narrow-spectrum, bactericidal antimycobacterial agent with good wild-type activity. BRD-8000.3 can be used for the research of tuberculosis[1].
BRD-8000.3, as a specific EfpA inhibitor, is a narrow-spectrum, bactericidal antimycobacterial agent with good wild-type activity[1]. | [References]
[1]. Johnson EO, et al. Large-Scale Chemical-Genetic Strategy Enables the Design of Antimicrobial Combination Chemotherapy in Mycobacteria. ACS Infect Dis. 2020;6(1):56-63. |
|
|